ABSTRACT: Heterotopic ossification (HO) is the abnormal formation of bone in soft tissues and is a frequent complication of hip replacement surgery. Heterotopic ossifications are described to develop via endochondral ossification and standard treatment is administration of indomethacin. It is currently unknown how indomethacin influences heterotopic ossification on a molecular level; therefore, we aimed to determine whether indomethacin might influence heterotopic ossification via impairing the chondrogenic phase of endochondral ossification. Progenitor cell models differentiating in the chondrogenic lineage (ATDC5, primary human bone marrow stem cells and ex vivo periosteal agarose cultures) were treated with increasing concentrations of indomethacin and a decrease in gene-and protein expression of chondrogenic and hypertrophic markers (measured by RT-qPCR and immunoblotting) as well as decreased glycosamino-glycan content (by alcian blue histochemistry) was observed. Even when hypertrophic differentiation was provoked, the addition of indomethacin resulted in decreased hypertrophic marker expression. Interestingly, when mature chondrocytes were treated with indomethacin, a clear increase in collagen type 2 expression was observed. Similarly, when ATDC5 cells and bone marrow stem cells were pre-differentiated to obtain a chondrocyte phenotype and indomethacin was added from this time point onward, low concentrations of indomethacin also resulted in increased chondrogenic differentiation. Indomethacin induces differential effects on in vitro endochondral ossification, depending on the chondrocyte's differentiation stage, with complete inhibition of chondrogenic differentiation as the most pronounced action. This observation may provide a rational behind the elusive mode of action of indomethacin in the treatment of heterotopic ossifications. 1,2 The causes of HO include traumatic, neurogenic, and genetic origins. Most commonly, HO is seen as a frequent complication of total hip arthroplasty, where it can result in pain and restrict range of motion.
Heterotopic ossification (HO) is the abnormal formation of mature lamellar bone in non-osseus soft tissues and was first described by Reidel in 1883, and by Dejerne and Ceiler in 1918 in patients with trauma from Word War I. 1, 2 The causes of HO include traumatic, neurogenic, and genetic origins. Most commonly, HO is seen as a frequent complication of total hip arthroplasty, where it can result in pain and restrict range of motion. 1, 2 In the absence of prophylaxis, the incidence of heterotopic ossification is reported to be as high as 60-75%. 3 The precise pathophysiology of HO is still unclear, but is believed to be the result of inappropriate differentiation of progenitor cells influenced by local and systemic factors. 4 Although not completely definite, there are studies that report that HO originates by endochondral ossification. 5, 6 During endochondral ossification mesenchymal progenitors gradually differentiate into chondrocytes, become mineralized hypertrophic chondrocytes which die by apoptosis (chondrogenic phase) or transdifferentiate into osteoblasts. [7] [8] [9] The remaining mineralized extracellular matrix provides a molecular scaffold for osteoblasts and osteoclasts to adhere to and remodel, setting the stage for de novo bone deposition (osteogenic phase). [10] [11] [12] Especially, the role of bone morphogenetic proteins (BMPs) has been studied extensively in ectopic bone formations as HO. Urist and colleagues showed that demineralized bone matrix, which naturally contains BMPs, induced ectopic bone formation when implanted in muscles. 13 In addition, BMPinduced HO in an animal model could be inhibited by the BMP antagonist Noggin in a dose-dependent manner 14 and mice lacking Noggin show over activity of the BMPs resulting in exuberant HO formation. 15 BMP-2 is reported to induce endochondral and intramembranous ossification in vitro and in vivo. [16] [17] [18] [19] [20] BMPs can regulate Runt-related transcription factor 2 (Runx2) via BMP-activated Smad signaling, inducing expression of Collagen type X (Col10a1) and alkaline phosphatase (Alp), thereby playing an important role in chondrocyte mineralization. [21] [22] [23] Furthermore, BMP-2 is also able to directly influence the major chondrogenic transcription factor Sox9, 24 thereby also influencing early chondrogenic differentiation.
Other factors that are described to influence HO development are prostaglandins.
1,2 Urinary excretion of Prostaglandin E 2 (PGE 2 ) is a recommended indicator of early HO and the PGE 2 blocking agent indomethacin is highly effective in slowing down HO formation. [25] [26] [27] However, it is currently unknown how indomethacin influences HO formation via endochondral ossification on a molecular level and how BMP-2 influences this process. Therefore, we aimed to define whether indomethacin influences the early, chondrogenic, phase of endochondral ossification.
MATERIALS AND METHODS
ATDC5 Cell Culture ATDC5 were cultured, as described before, 28 in proliferation medium consisting of DMEM/F12 (Dulbecco's Modified Eagle Medium; Invitrogen, Carlsbad, CA), 5% FCS (Fetal Calf Serum; PAA, Pasching, Austria), 1% antibiotic/antimycotic (Invitrogen), and 1% NEAA (non-essential amino acids; Invitrogen). ATDC5 were differentiated in differentiation medium comprising proliferation medium supplemented with 10 mg/ml insulin (Sigma-Aldrich, St. Louis, MO), 10 mg/ml transferrin (Roche, Indianapolis, IN), and 30 nM sodium selenite (Sigma-Aldrich). Cells were plated at 6,400 cells/cm 2 and chondrogenic differentiation was initiated by adding differentiation medium. BMP-2 (SigmaAldrich) was used in 30 ng/ml. Indian Hedgehog (Ihh; Sigma-Aldrich) was used at 150 ng/ml. Indomethacin (Sigma-Aldrich) was used at 2, 20, and 200 mM concentrations. PGE 2 (Cayman Chemicals, Ann Arbor, MI) was used at 10 nM and differentiation medium was refreshed daily.
hBMSC Isolation and Cell Culture Human bone marrow stem cells (hBMSCs) were obtained from iliac crest bone marrow aspirate from young, genetically healthy individuals (MEC MUMC approval 08-4-056). hBMSCs were isolated using Ficoll-Paque PLUS (Amersham Pharmacia, Diegem, Belgium) and cultured and differentiated as previously described. 28 Culture medium consisted of DMEM high glucose (Invitrogen), 10% FCS, 1% antibiotic/ antimycotic, and 1% NEAA. Chondrogenic differentiation was performed in monolayer by plating passage five cells at 30,000 cells/cm 2 and adding differentiation medium. Differentiation medium consisted of proliferation medium supplemented with 1% ITS (Invitrogen), 50 mg/ml L-ascorbic acid-2-phosphate (Sigma-Aldrich) and 1 ng/ml TGFb3 (Transforming growth factor b3; R&D, Minneapolis, MN). 28, 29 Indomethacin was used at 2 mM concentration.
Periosteum Agarose Culture (PAC) As previously described, 30 periosteum was harvested from the proximal tibia of skeletally mature NZW (New Zealand white)-rabbits. Post-mortem animals were obtained from an unrelated study, no ethical approval was necessary. Periosteum was prepared as a 3 Â 3 mm piece and embedded between a layer of high melting agarose (1%) and low melting agarose (1%) according to O'Driscoll et al., 31 and proliferation medium (DMEM/F12, 10% FCS, 1% P/S, 1% NEAA) was added. After overnight incubation, medium was changed to differentiation medium (proliferation medium supplemented with 1% ITS, 50 mg/ml L-ascorbic acid-2-phosphate, 10 ng/ml TGFb3 and 30 ng/ml BMP-2) and PACs were differentiated for 20 days with medium changes every 3 days. Indomethacin was used at 2 mM concentration.
Human Articular Chondrocyte (HAC) Isolation and Cell Culture Chondrocytes were obtained from the unaffected regions of OA cartilage from total knee arthroplasty (MEC approval 08-4-028). Isolation and culture of chondrocytes were performed as described before. 32 Briefly, cartilage was separated from the subchondral bone and cut into small pieces using a sterile surgical blade. Cartilage pieces were digested overnight at 37˚C in collagenase type II solution (300 U/ml in HEPES buffered DMEM/F12 supplemented with antibiotics) under continuous agitation. The preparation was rinsed with 0.9% NaCl over a 70 mm cell strainer and plated in culture flasks. Cells were cultured in a humidified atmosphere at 37˚C, 5% CO 2 and after reaching confluency the cells were continuously passaged 1:2 until passage 2. Culture medium consisted of DMEM/F12 (Invitrogen), 10% FCS (PAA), 1% antibiotic/antimycotic (Invitrogen), and 1% NEAA (Invitrogen). For experiments, cells were plated at 30,000 cells/cm 2 and medium was changed every 2 days until day 7. Indomethacin was used at 2 mM concentration.
RT-qPCR
For RNA isolation, cells were washed three times with 0.9% NaCl and disrupted with 500 ml Trizol (Invitrogen). To isolate total RNA from PAC cultures, tissue was cut in pieces and soaked overnight in 500 ml Trizol at 4˚C. RNA isolation, RNA quantification by ultraviolet (UV)-spectrometry (Nanodrop, Thermo Scientific, Waltham, MA), and cDNA synthesis were performed as described before. 28 Real time quantitative PCR (RT-qPCR) was performed using Mesagreen qPCR mastermix plus for SYBR 1 Green (Eurogentec, Seraing, Belgium). An ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA) was used for amplification: initial denaturation 95˚C for 10 min, followed by 40 cycles of DNA amplification (denaturing 15 s at 95˚C and annealing 1 min at 60˚C). Data were analyzed using the standard curve method, mRNA expression was normalized to a reference gene (b-actin [ATDC5, rPACs] and 28S rRNA [hBMSCs and HACs]) and gene expression was calculated as fold increase as compared to day 0. Validated primer sequences are depicted in Table 1 .
Immunoblotting Cells were washed with 0.9% NaCl and lysed in RIPA buffer. Extracts were sonicated on ice using the Soniprep 150 (MSE, London, UK) at amplitude 10 for 14 cycles (1 s sonication and 1 s pause). Insoluble material was removed by centrifugation (13,000g, 4˚C). Protein concentration was determined using the bicinchoninic acid (BCA) protein assay (Sigma-Aldrich). Polypeptides were separated by SDS-PAGE (samples were equally loaded) and transferred to nitrocellulose membranes by electroblotting. Primary antibodies for immunodetection were polyclonal goat antiCol2a1 (Southern Biotech, Birmingham, AL), polyclonal rabbit anti-Col10a1 (Calbiochem, Darmstadt, Germany) and mouse monoclonal anti-a-GAPDH (Fitzgerald, Acton, MA). Bound primary antibodies were detected with secondary immunoglobulins conjugated with horseradish peroxidase (DakoCytomation, Glostrup, Denmark) and visualized by enhanced chemiluminescence (ECL). ECL signals were quantified using ImageJ 1.46f software. Relative differences, corrected for background and housekeeper, were determined as compared to control conditions.
Alcian Blue Staining
Glycosaminoglycan content was detected by Alcian blue staining. Cells were washed with 0.9% NaCl and fixed with 4% paraformaldehyde (Merck, Darmstadt, Germany) in phosphate buffered saline for 10 min at room temperature, washed with water and air dried. After overnight incubation with 1% Alcian blue (Acros Organics, Geel, Belgium) in 0.1 M HCl at room temperature, cells were washed six times and Alcian blue was extracted by incubation with Guanidine-HCl (6 M) (Sigma-Aldrich) for 2 h under continuous agitation. Extracted Alcian blue was determined spectrophotometrically at 645 nm using a plate reader (Multiskan FC, Thermo Scientific, Waltham, MA).
Cell Proliferation
Cells were washed with 0.9% NaCl and fixated with 4% paraformaldehyde (Merck) in phosphate buffered saline for 10 min at room temperature, washed with water, and air dried. Cells were incubated with 0.1% Crystal-violet (SigmaAldrich) for 30 min at room temperature and washed six times with water. Crystal-violet was extracted from the cells by incubation with 10% acetic acid for 15 min under continuous agitation. Extracted Crystal-violet was determined spectrophotometrically at 590 nm using a plate reader (Multiskan FC, Thermo Scientific).
Alkaline Phosphatase Activity Cells were lysed in collection buffer (1.5 M Tris-HCl pH 9.0; 2% (v/v) Triton X-100) and homogenized by sonication (Soniprep 150 MSE). Insoluble material was removed by centrifugation (5 min; 13,000g; 4˚C). Total protein concentration was determined by BCA protein assay. ALP enzyme activity was determined by in-time measuring ALPdependent enzymatic conversion of p-nitrophenyl phosphate to p-nitrophenol in buffer containing 1.5 M Tris-HCl; pH 9.0, 1 mM ZnCl 2 , 1 mM MgCl 2 , and 7.5 mM p-nitrophenyl phosphate. Substrate conversion was spectrophotometrically quantified at 405 nm and p-nitrophenol concentrations were determined via a p-nitrophenol calibration series. Values were normalized to total protein concentration and ALP enzyme activity was calculated in units ( U ¼ 1 mmol/min/mg).
Histochemistry
PACs were decalcified in formalin/EDTA, dehydrated following standard procedures and embedded in paraffin. Before histochemistry, tissue sections (5 mm) were deparafinized and rehydrated using standard protocols. Proteoglycans were stained with Safranin-O (0.1%) and counterstained with Fast Green (0.1%). Stained sections were dehydrated and mounted in Histomount (Thermo Shandon, Waltham, MA) for microscopic analysis. Safranin-O staining (red staining intensity) was quantified using Image J. Cell profiler 2.1.1 (Broad Institute, Cambridge, MA) was used to calculate the percentage hypertrophic cells to total cell number.
PGE 2 Measurement
Prostaglandin production of PGE 2 was determined in culture medium. Culture medium from different chondrogenic time points was stored in aliquots at À80˚C until analysis. PG concentration was determined by a standardized EIA according to the manufacturers' protocol (Cayman Chemical).
Statistics
In the figures based on ATDC5 bars represent average value of three individual experiments (performed in triplicate; 3 Â 3 samples) and error bars represent mean AE standard error of mean (sem). In the experiments using hBMSCs, HACs, or rPACs, all experiments were performed in triplicate from three independent donors (n ¼ 3). Statistical significance (p < 0.05) was determined by ANOVA with Bonferroni post hoc analysis using GraphPad PRISM 5.0 (La Jolla, CA).
RESULTS

Indomethacin Inhibits Chondrogenic Differentiation of Progenitor Cells
To determine whether indomethacin influences the chondrogenic phase of endochondral ossification, we exposed chondrogenically differentiating progenitor cells to indomethacin. For this purpose, the ATDC5 cell line was used. Differentiation of these cells follows a well-defined and -established endochondral program from undifferentiated chondroprogenitor to chondrocytes with a hypertrophic phenotype. 33, 34 The progenitor ATDC5 cells were differentiated under control conditions and with increasing concentrations of indomethacin (0-200 mM). To verify indomethacin action, prostaglandin E 2 levels were measured in culture medium and all concentrations showed significantly decreased PGE 2 levels at days 10 and 14 in differentiation (Fig. 1A) . In control conditions, ATDC5 cells displayed a chondrogenic phenotype at day 10 and further in differentiation, as determined by increased mRNA expression of collagen type II (Col2a1), SRY (sex determining region Y) box 9 (Sox9), parathyroid hormone related peptide (PTHrP), and glycosaminoglycan (GAG) content (Fig. 1B, D , and C; white bars).
A chondrocyte hypertrophic phenotype is present at day 14 in ATDC5 differentiation as determined by collagen type X (Col10a1), Runx2, alkaline phosphatase (ALP), and indian hedgehog (Ihh) mRNA expression ( Fig. 1D and E ; white bars). Indomethacin added from the progenitor phase on and further throughout chondrogenic differentiation of ATDC5, resulted in a decrease in both chondrogenic-and hypertrophic marker mRNA expression during the course of differentiation (Fig. 1B, D , and E). Protein analysis confirmed Col2a1 and Col10a1 mRNA results (Fig. 1F) . Also, GAG content was decreased with increasing concentrations of indomethacin (Fig. 1C) . As proliferation is an important aspect of ATDC5 differentiation (and chondrogenesis), 33 the effects of indomethacin on cell proliferation were determined. Indomethacin affected the cell proliferation rate at all of the tested concentrations (Fig. 1F) , but did not affect cell viability at this time point (Fig. S1A) . Also, the inhibitory effect of indomethacin on chondrogenic differentiation of ATDC5 cells was reversible when treatment of indomethacin was stopped and cells were cultured for additional time (Fig. S1B) . Overall, these results show that indomethacin decreases the chondrogenic outcome of ATDC5 cells.
Whereas, indomethacin had an inhibitory effect on chondrogenic marker expression of Col2a1, Sox9, and PTHrP, supplementing these cultures with PGE 2 was able to significantly rescue the expression of these markers ( Fig. 2A) . This was also confirmed for GAG content (Fig. 2C) . Similar results were obtained for hypertrophic marker gene expression of Col10a1, Runx2, Ihh, and ALP activity (Fig. 2B and D) . Also, the decreased proliferation rate of differentiating ATDC5 cultures as a result of indomethacin treatment was partly rescued by addition of PGE 2 (Fig. 2E) . Of note, PGE 2 alone was able to increase Col10a1 and Runx2 mRNA expression as well as ALP activity in the control (0 mM) condition. Together, these data indicate that the decrease in chondrogenic outcome of ATDC5 by indomethacin is, at least in part, due to inhibition of PGE 2 synthesis.
As indomethacin prevents HO formation in vivo in a chondrocyte hypertrophy/mineralization stimulating environment, we provoked hypertrophic differentiation in ATDC5 cells by addition of BMP-2 (30 ng/ml) 30 or Ihh (150 ng/ml), both well-known inducers of ectopic bone formation.
13,35 BMP-2 or Ihh addition resulted in similar expression levels of Col2a1, Sox9, and PTHrP mRNAs as compared to control, but significantly increased the mRNA expression of chondrocyte hypertrophy markers Col10a1, Runx2, ALP, Ihh, and osteopontin (OPN) (Fig. 3A) . Treatment with increasing concentrations of indomethacin resulted in decreased PGE 2 levels confirming functional indomethacin action under BMP-2 or Ihh stimulation (Fig. 3B) . When chondrocyte hypertrophy was provoked by BMP-2 or Ihh, the addition of indomethacin resulted in significantly decreased chondrogenic (Col2a1, Sox9, and PTHrP) and hypertrophy marker expression as determined by Col10a1, Runx2, ALP, OPN, and Ihh expression ( Fig. 3C and D) . For BMP-2, results were confirmed on protein level (Fig. 3E) . To verify our ATDC5 findings in primary mesenchymal progenitor cells, we supplemented the differentiation medium of hBMSCs (n ¼ 4) with 2 mM indomethacin and determined COL2A1, SOX9, RUNX2, and COL10A1 mRNA expression over time. Ã Indicates p < 0.05, and is determined for indomethacin conditions compared to control and for conditions with PGE 2 as compared to without PGE 2 .
INDOMETHACIN AFFECTS ENDOCHONDRAL OSSIFICATION
In agreement with the ATDC5 chondrogenic differentiation results, indomethacin exposure resulted in decreased chondrogenic outcome during the course of differentiation (Fig. 4A ). In addition, we used an ex vivo periosteal tissue culture where progenitor cellcontaining periosteal tissue undergoes endochondral ossification between two layers of agarose (periosteum agarose culture; PAC) in the presence of TGFb3 and BMP-2.
30,31,36 After 21 days Col2a1 and Aggrecan (Acan) mRNA expression and a clear Safranin-O staining are present, indicative of chondrogenic differentiation, which is combined with increased Col10a1 and Runx2 mRNA expression and a hypertrophic chondrocyte morphology (Fig. 4B and C) . Addition of indomethacin (see Fig. S2 for confirmation of PGE 2 inhibition) resulted in a decreased Col2a1 and Acan levels and Safranin-O staining as well as reduced Col10a1 and Runx2 mRNA expression, combined with significantly reduced presence of hypertrophic chondrocytes. Together, these data show that indomethacin decreases the outcome of the chondrogenic phase of endochondral ossification.
Indomethacin Has Differential Effects on Chondrogenic Outcome Depending on Differentiation Stage
In the above presented data, indomethacin was added from the onset of differentiation (t ¼ 0) onward, however indomethacin might have an alternate effect on cells in a different, more mature, differentiation stage. This is relevant as at present it is unclear if indomethacin prevents HO formation or inhibits mineralization in developing HO's. To study this possibility, we determined whether indomethacin influenced ATDC5 chondrogenic differentiation differently depending of differentiation stage. In addition to treatment with indomethacin (see Fig. S2 for confirmation of PGE 2 inhibition) from t ¼ 0 onward, we also included a condition where indomethacin was added from t ¼ 2, 4, 6, 8, and 10 days in differentiation onward and cells were analyzed at day 14 in differentiation. Interestingly, when differentiating ATDC5 cells were treated with indomethacin from t ¼ 10 days onward, when the cells have acquired a chondrocyte-like phenotype (Fig. 1) , a significant increase in Col2a1 and Col10a1 mRNA expression was observed at day 14 in differentiation ( Fig. 5A and B) . Similar results were obtained for Sox9 and Runx2 mRNA expression levels as well as GAG content and ALP activity (Fig. 5C ). As addition of indomethacin from the chondrocyte-like stage (t ¼ 10 days) was only for 4 days (cells were harvested at t ¼ 14 days) when compared to condition, where indomethacin was present from the start of the experiment (treatment for 14 days), we needed to exclude duration of treatment as potential confounding factor. Therefore a condition was included where we treated the cells in the chondrocyte-like stage (from t ¼ 10 days) for 14 days with indomethacin (until day 24). Also in this condition, treatment of indomethacin from chondrocyte-like stage resulted in increased chondrogenic and hypertrophic marker expression (Fig. 5C) . Similarly, when hBMSCs were pre-differentiated for 14 days and indomethacin was added from this time point onward until day 28 (cells were harvested at day 28), a clear increase in COL2A1, SOX9, and ACAN mRNA expression was observed (Fig. 5C) . No significant effects were observed for COL10A1, RUNX2, and ALP mRNA expression (Fig. 5D ).
When these results are compared to experiments with primary mature human articular chondrocytes Figure 4 . Indomethacin inhibits chondrogenic differentiation of primary progenitor cells. hBMSCs and rPACs from four individual donors were differentiated in the chondrogenic lineage (control; white bars) and with indomethacin (2 mM, gray bars). (A) Induction of COL2A1, SOX9, RUNX2, and COL10A1 mRNA expression was determined by RT-qPCR at days 7, 14, 21, and 28 in hBMSC chondrogenic differentiation, relatively to day 0 conditions and normalized for 28S rRNA expression. (B) Periosteum agarose cultures (PAC's) were differentiated in the presence of TGFb3 (10 ng/ml) and BMP-2 (30 ng/ml) for 21 days. Induction of Col2a1, Acan, Runx2, and Col10a1 mRNA expression was determined by RT-qPCR at day 21 in chondrogenic rPAC differentiation, relatively to day 0 conditions and normalized for 28S rRNA expression. (C) rPAC samples were stained with Safranin-O/Fast green to visualize proteoglycans. Intensity (red staining) of Safranin-O staining was quantified using Image J software. Percentage hypertrophic cells was calculated relatively to total cell number. In graphs, error bars represent mean AE s.e.m. Ã Indicates p < 0.05, and is determined for indomethacin conditions compared to control.
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(HACs, n ¼ 3), treated with indomethacin, a clear increase in COL2A1, SOX9, and ACAN expression was observed in mature chondrocytes as well (Fig. 5C ) and no significant effect was seen on COL10A1, RUNX2, or ALP mRNA expression (Fig. 5D) . In all samples, indomethacin action was confirmed by decreased PGE 2 levels ( Fig. S2B and C) . Taken together, these data indicate that indomethacin has differentiation stagedependent effects on the outcome of chondrogenic differentiation. ATDC5 cells were differentiated and indomethacin was added from start of experiment (t ¼ 0) or day 10 in differentiation until day 14 or from day 10 until day 24 in differentiation. Induction of Col2a1, Sox9, Col10a1, and Runx2 mRNA expression was determined by RT-qPCR, relatively to day 0 conditions and normalized for b-Actin mRNA expression. GAG content and ALP activity were determined and calculated relatively to day 0 conditions. (D) hBMSCs (n ¼ 4 individual donors) were differentiated for 14 days in the chondrogenic lineage, after which treatment of indomethacin (2 mM; gray bars) started until day 28. Mature HACs from 3 individual donors (passage 2) were also treated with indomethacin (2 mM, gray bars) for 7 days. Induction of COL2A1, SOX9, and ACAN mRNA expression was determined by RT-qPCR, relatively to day 0 conditions for hBMSCs and to control conditions for HACs and normalized for 28S rRNA expression. (E) Similar to (D), but for COL10A1, RUNX2, and ALP mRNA expression. In graphs, error bars represent mean AE s.e.m. Ã Indicates p < 0.05, and is determined for indomethacin conditions compared to control. 
DISCUSSION
HO is, by definition, bone formation within soft tissue and Chalmers et al. described three essential conditions for the formation of HO; precursor cells capable of differentiation toward osteogenic tissue, inducing agents and a permissive environment. 37 The pathogenesis of HO is thought to involve differentiation of progenitor cells of mesenchymal origin toward bony tissue, probably via endochondral ossification. 5, 6, 38 This cell biological background was the reason to address our hypothesis in cell models capable of chondrogenic and hypertrophic differentiation, such as the ATDC5 cell line, 39 hBMSCs, 40 and PAC. 31 This gives us the opportunity to specifically study the mode of action of indomethacin on different defined moments in the chondrogenic phase of endochondral ossification as a model for HO development in vitro. We have shown in previous work that these in vitro models for chondrogenic and hypertrophic differentiation in monolayer respond to important inducers of mineralization such as BMP-2, by increasing expression of hypertrophic markers even further 30, 40 (Fig. 3A) . Bisphosphonates and non-steroidal anti-inflammatory drugs such as indomethacin are used to treat HO. 2 However, no consensus is reached on when treatment should begin. We therefore set out to investigate the effect of indomethacin on different phases of in vitro chondrogenic and hypertrophic differentiation. Our data show that indomethacin inhibits chondrogenic and hypertrophic differentiation from progenitor cells when present from the early start of differentiation (Figs.  1-4) ; while exposure of (pre)differentiated chondrocytes to indomethacin did not negatively influence a chondrogenic phenotype, rather stimulating it (Fig. 5 ). This suggests that indomethacin has differential effects on chondrogenic differentiation depending on the cell's differentiation stage. Translating this to the in vivo situation, it suggests that the mode of action of indomethacin in the treatment of HO may be by preventing HO formation by inhibiting early chondrogenic differentiation of local mesenchymal progenitor cells, rather than slowing down further progression of already developed HOs. Importantly, our data suggest that the post-operative administration moment of indomethacin may be critical. Immediate post-operative prophylactic administration may inhibit HO development via preventing chondrogenic differentiation, while delayed initiation of post-operative administration may even increase the risk for HO development by stimulating chondrogenic differentiation. However, it has to be acknowledged that relevant animal models for HO are needed to determine the relevance of our findings in the actual in vivo context.
It has been postulated that during inflammation, a condition often accompanying immobilization or trauma and essential in a normal wound healing response, secretion of BMPs is increased from bone tissue. BMPs are in turn capable of provoking ectopic bone formation from mesenchymal progenitor cells. 41 In addition, the involvement of prostaglandin E 2 (PGE 2 ) as central (inflammatory) mediator in endochondral ossification of progenitor cells has also been proposed. 2, 42 Indeed, our data presented in Figure 2 show that the effects of indomethacin could be partly rescued by PGE 2 . We and others have previously shown that a mild inflammatory environment is able to trigger chondrogenic differentiation of progenitor cells in vitro, 28 and that the NF-ĸB/p65 complex plays an essential role in this process 28, 43, 44 The levels of PGE 2 and its synthesizing enzyme cyclooxygenase (COX)-2 during early chondrogenic differentiation are under control of NF-ĸB/p65 as well and are positively influenced by BMP-2. Moreover PGE 2 is able to regulate BMP2 expression in mesenchymal progenitor cells, 45 inducing a positive feedback loop to stimulate cell differentiation. We therefore postulate that heterotopic ossification formation is stimulated by an inflammatory environment, 38 eventually in combination with additional secreted activating mediators such as BMPs. Indomethacin then acts to preventing the formation of HOs by inhibiting an early inflammatory environment and prostaglandin synthesis in the involved mesenchymal progenitor cells.
Indomethacin is a non-specific COX inhibitor (Fig.  S3) and might exert its function via inhibition of COX-1 and/or COX-2 function. Both COX isoforms catalyze the same enzymatic reactions but they have remarkable differences regarding their expression levels and their ability to respond to various stimuli.
46-49 COX-1 is constitutively expressed by most mammalian cells and regarded as the "housekeeping" cyclooxygenase. On the other hand, COX-2 expression is low in most tissues but can be rapidly induced upon exposure to various stimuli such as inflammation and injury. Our recent data indicate that specific inhibition of COX-1 or COX-2 during the early phase of chondrogenic differentiation in above in vitro models results in differential prostaglandin expression profiles and differences in chondrogenic outcome. 50 Specific inhibition of COX-1 completely prevented differentiation of progenitor cells, whereas inhibition of COX-2 resulted in decreased Col10a1 expression, while Col2a1 remained unaffected. 30, 50 Presented data closely resemble our preliminary specific COX-1 inhibitory data and suggest that indomethacin may prevent differentiation of mesenchymal progenitor cells in a COX-1 dominant fashion. Why indomethacin differently influences the chondrogenic outcome, depending on the chondrocyte's differentiation stage, remains unclear. A possible explanation includes the cell's differentiation status and sensitivity to indomethacin, potentially induced by differentiation stage-dependent COX-1 and COX-2 expression levels. Furthermore, we observed that, despite a significant PGE 2 inhibitory action (Fig. 1A) , the effect of indomethacin on the expression of Col2a1 and Col10a1 expression was depending on the concentration of indomethacin ( Fig. 1B and E ). It appears that PGE 2 concentrations secreted in the culture medium are relatively high and that a high percentage of PGE 2 synthesis can be inhibited by low concentrations of indomethacin without having a large effect on chondrogenic marker expression. We excluded cytotoxicity as a possible explanation (Fig. S1 ) and also COX enzyme isoform inhibition specificity for indomethacin is stable in the concentrations tested (Fig. S3) . We speculate that a critical tipping point in the magnitude of inhibition of PGE 2 synthesis is reached between 2 and 20 mM indomethacin, resulting in the deleterious effects on chondrogenic marker expression as reported.
In conclusion, indomethacin induces differential effects on in vitro endochondral ossification, depending on the chondrocyte's differentiation stage, with complete inhibition of chondrogenic differentiation as the most pronounced action. This observation may provide a rational behind the elusive mode of action of indomethacin in the treatment of HO.
